(ELAN) Elanco Animal Health - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US28414H1032
Stock: Pet Health, Farm Animals, Therapeutics, Vaccines, Parasiticides
Total Rating 65
Risk 68
Buy Signal -0.33
| Risk 5d forecast | |
|---|---|
| Volatility | 54.1% |
| Relative Tail Risk | -21.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.79 |
| Alpha | 96.37 |
| Character TTM | |
|---|---|
| Beta | 1.758 |
| Beta Downside | 1.150 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.10% |
| CAGR/Max DD | 0.71 |
EPS (Earnings per Share)
Revenue
Description: ELAN Elanco Animal Health March 05, 2026
Elanco Animal Health (ELAN) is a global animal health company. It develops, manufactures, and markets products for both pets and farm animals.
The companys pet health segment includes parasiticides, vaccines, and therapeutics. These products address issues like fleas, ticks, and internal parasites, as well as pain, otitis, and osteoarthritis. The animal health sector is characterized by ongoing research and development due to evolving disease threats and pet owner demand for advanced care.
For farm animals, Elanco provides products that improve health and wellbeing for livestock such as cattle, swine, and poultry. This includes medicated feed additives, antibiotics, vaccines, and insecticides. The farm animal health market is driven by global food demand and the need for efficient, healthy livestock production.
Elanco distributes its products through third-party distributors and independent retailers, and directly to farm animal producers and veterinarians. This multi-channel distribution model is common in the animal health industry.
To deepen your understanding of Elancos financial performance, consider exploring its detailed financials on ValueRay.
Headlines to watch out for
- Pet parasiticides sales growth
- Farm animal product demand fluctuations
- Regulatory approval of new animal health drugs
- Raw material cost volatility impacts margins
- Global livestock disease outbreaks affect revenue
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -232.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.95 > 1.0 |
| NWC/Revenue: 39.47% < 20% (prev 42.80%; Δ -3.33% < -1%) |
| CFO/TA 0.04 > 3% & CFO 560.0m > Net Income -232.0m |
| Net Debt (3.47b) to EBITDA (722.0m): 4.81 < 3 |
| Current Ratio: 2.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (496.9m) vs 12m ago 0.51% < -2% |
| Gross Margin: 46.45% > 18% (prev 0.43%; Δ 4.60k% > 0.5%) |
| Asset Turnover: 36.31% > 50% (prev 35.19%; Δ 1.12% > 0%) |
| Interest Coverage Ratio: 0.16 > 6 (EBITDA TTM 722.0m / Interest Expense TTM 266.0m) |
Altman Z'' 0.05
| A: 0.14 (Total Current Assets 3.46b - Total Current Liabilities 1.60b) / Total Assets 13.36b |
| B: -0.16 (Retained Earnings -2.18b / Total Assets 13.36b) |
| C: 0.00 (EBIT TTM 42.0m / Avg Total Assets 12.99b) |
| D: -0.34 (Book Value of Equity -2.32b / Total Liabilities 6.81b) |
| Altman-Z'' Score: 0.05 = B |
Beneish M -3.14
| DSRI: 1.00 (Receivables 940.0m/886.0m, Revenue 4.71b/4.44b) |
| GMI: 0.93 (GM 46.45% / 43.01%) |
| AQI: 0.95 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.06 (Revenue 4.71b / 4.44b) |
| TATA: -0.06 (NI -232.0m - CFO 560.0m) / TA 13.36b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of ELAN shares?
As of March 22, 2026, the stock is trading at USD 23.98 with a total of 2,865,721 shares traded.
Over the past week, the price has changed by +4.53%, over one month by -4.00%, over three months by +7.53% and over the past year by +126.65%.
Over the past week, the price has changed by +4.53%, over one month by -4.00%, over three months by +7.53% and over the past year by +126.65%.
Is ELAN a buy, sell or hold?
Elanco Animal Health has received a consensus analysts rating of 3.87.
Therefore, it is recommended to buy ELAN.
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | 20% |
| Analysts Target Price | 28.8 | 20% |
ELAN Fundamental Data Overview March 19, 2026
P/E Forward = 22.2717
P/S = 2.6551
P/B = 1.777
P/EG = 4.0519
Revenue TTM = 4.71b USD
EBIT TTM = 42.0m USD
EBITDA TTM = 722.0m USD
Long Term Debt = 3.94b USD (from longTermDebt, last quarter)
Short Term Debt = 74.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.47b USD (from netDebt column, last quarter)
Enterprise Value = 15.99b USD (12.52b + Debt 4.02b - CCE 545.0m)
Interest Coverage Ratio = 0.16 (Ebit TTM 42.0m / Interest Expense TTM 266.0m)
EV/FCF = 56.31x (Enterprise Value 15.99b / FCF TTM 284.0m)
FCF Yield = 1.78% (FCF TTM 284.0m / Enterprise Value 15.99b)
FCF Margin = 6.02% (FCF TTM 284.0m / Revenue TTM 4.71b)
Net Margin = -4.92% (Net Income TTM -232.0m / Revenue TTM 4.71b)
Gross Margin = 46.45% ((Revenue TTM 4.71b - Cost of Revenue TTM 2.52b) / Revenue TTM)
Gross Margin QoQ = 39.34% (prev 53.39%)
Tobins Q-Ratio = 1.20 (Enterprise Value 15.99b / Total Assets 13.36b)
Interest Expense / Debt = 2.27% (Interest Expense 91.0m / Debt 4.02b)
Taxrate = 21.0% (US default 21%)
NOPAT = 33.2m (EBIT 42.0m * (1 - 21.00%))
Current Ratio = 2.17 (Total Current Assets 3.46b / Total Current Liabilities 1.60b)
Debt / Equity = 0.61 (Debt 4.02b / totalStockholderEquity, last quarter 6.55b)
Debt / EBITDA = 4.81 (Net Debt 3.47b / EBITDA 722.0m)
Debt / FCF = 12.23 (Net Debt 3.47b / FCF TTM 284.0m)
Total Stockholder Equity = 6.61b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.79% (Net Income -232.0m / Total Assets 13.36b)
RoE = -3.51% (Net Income TTM -232.0m / Total Stockholder Equity 6.61b)
RoCE = 0.40% (EBIT 42.0m / Capital Employed (Equity 6.61b + L.T.Debt 3.94b))
RoIC = 0.31% (NOPAT 33.2m / Invested Capital 10.77b)
WACC = 9.81% (E(12.52b)/V(16.54b) * Re(12.39%) + D(4.02b)/V(16.54b) * Rd(2.27%) * (1-Tc(0.21)))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.42%
[DCF] Terminal Value 66.73% ; FCFF base≈325.6m ; Y1≈254.2m ; Y5≈164.1m
[DCF] Fair Price = N/A (negative equity: EV 2.29b - Net Debt 3.47b = -1.18b; debt exceeds intrinsic value)
EPS Correlation: -31.23 | EPS CAGR: -23.79% | SUE: 0.41 | # QB: 0
Revenue Correlation: 10.45 | Revenue CAGR: -1.83% | SUE: 2.47 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.29 | Chg7d=+0.002 | Chg30d=-0.001 | Revisions Net=+4 | Analysts=10
EPS current Year (2026-12-31): EPS=1.04 | Chg7d=-0.002 | Chg30d=+0.011 | Revisions Net=+7 | Growth EPS=+10.8% | Growth Revenue=+6.1%
EPS next Year (2027-12-31): EPS=1.17 | Chg7d=-0.002 | Chg30d=+0.014 | Revisions Net=+3 | Growth EPS=+12.0% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
P/S = 2.6551
P/B = 1.777
P/EG = 4.0519
Revenue TTM = 4.71b USD
EBIT TTM = 42.0m USD
EBITDA TTM = 722.0m USD
Long Term Debt = 3.94b USD (from longTermDebt, last quarter)
Short Term Debt = 74.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.47b USD (from netDebt column, last quarter)
Enterprise Value = 15.99b USD (12.52b + Debt 4.02b - CCE 545.0m)
Interest Coverage Ratio = 0.16 (Ebit TTM 42.0m / Interest Expense TTM 266.0m)
EV/FCF = 56.31x (Enterprise Value 15.99b / FCF TTM 284.0m)
FCF Yield = 1.78% (FCF TTM 284.0m / Enterprise Value 15.99b)
FCF Margin = 6.02% (FCF TTM 284.0m / Revenue TTM 4.71b)
Net Margin = -4.92% (Net Income TTM -232.0m / Revenue TTM 4.71b)
Gross Margin = 46.45% ((Revenue TTM 4.71b - Cost of Revenue TTM 2.52b) / Revenue TTM)
Gross Margin QoQ = 39.34% (prev 53.39%)
Tobins Q-Ratio = 1.20 (Enterprise Value 15.99b / Total Assets 13.36b)
Interest Expense / Debt = 2.27% (Interest Expense 91.0m / Debt 4.02b)
Taxrate = 21.0% (US default 21%)
NOPAT = 33.2m (EBIT 42.0m * (1 - 21.00%))
Current Ratio = 2.17 (Total Current Assets 3.46b / Total Current Liabilities 1.60b)
Debt / Equity = 0.61 (Debt 4.02b / totalStockholderEquity, last quarter 6.55b)
Debt / EBITDA = 4.81 (Net Debt 3.47b / EBITDA 722.0m)
Debt / FCF = 12.23 (Net Debt 3.47b / FCF TTM 284.0m)
Total Stockholder Equity = 6.61b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.79% (Net Income -232.0m / Total Assets 13.36b)
RoE = -3.51% (Net Income TTM -232.0m / Total Stockholder Equity 6.61b)
RoCE = 0.40% (EBIT 42.0m / Capital Employed (Equity 6.61b + L.T.Debt 3.94b))
RoIC = 0.31% (NOPAT 33.2m / Invested Capital 10.77b)
WACC = 9.81% (E(12.52b)/V(16.54b) * Re(12.39%) + D(4.02b)/V(16.54b) * Rd(2.27%) * (1-Tc(0.21)))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.42%
[DCF] Terminal Value 66.73% ; FCFF base≈325.6m ; Y1≈254.2m ; Y5≈164.1m
[DCF] Fair Price = N/A (negative equity: EV 2.29b - Net Debt 3.47b = -1.18b; debt exceeds intrinsic value)
EPS Correlation: -31.23 | EPS CAGR: -23.79% | SUE: 0.41 | # QB: 0
Revenue Correlation: 10.45 | Revenue CAGR: -1.83% | SUE: 2.47 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.29 | Chg7d=+0.002 | Chg30d=-0.001 | Revisions Net=+4 | Analysts=10
EPS current Year (2026-12-31): EPS=1.04 | Chg7d=-0.002 | Chg30d=+0.011 | Revisions Net=+7 | Growth EPS=+10.8% | Growth Revenue=+6.1%
EPS next Year (2027-12-31): EPS=1.17 | Chg7d=-0.002 | Chg30d=+0.014 | Revisions Net=+3 | Growth EPS=+12.0% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)